NVS · Basel, Switzerland
The Garage / Company file
Novartis
The result of the largest corporate merger in history that focused on shedding its chemical divisions to become a pure-play medicine research giant.
Market quote
—
Today
—
Symbol
NVS
The story / 5 turning points
1996
The Ciba-Geigy and Sandoz mega-merger
Novartis was born from the colossal, record-breaking merger of two historic Swiss chemical and pharmaceutical giants: Ciba-Geigy and Sandoz. The new entity was immediately one of the largest pharmaceutical companies in the world. However, the company was initially bloated, with vast interests in everything from agricultural chemicals to food products, forcing the new management team to undertake a massive, multi-year process of selling off divisions to focus exclusively on pharmaceuticals.
2015
The massive asset swap with GSK
In an attempt to redefine its strategic focus, Novartis executed a complex, multi-billion-dollar asset swap with GlaxoSmithKline (GSK). Novartis traded its oncology drug business for GSK’s vaccines and consumer products, effectively swapping one set of research priorities for another. It was a high-stakes, institutional-grade reorganization that signaled Novartis’s intent to focus its entire R&D budget on specialized, high-margin areas like immunology, neuroscience, and advanced cell therapy.
2022
The Sandoz spin-off and the focus on innovative medicine
Continuing its decades-long trend of simplification, Novartis officially spun off its massive generic-drug division, Sandoz, into an independent company. This move was designed to free Novartis from the low-margin business of making cheap, generic knock-off drugs. The firm finally became a "pure-play" innovative pharmaceutical company, betting its entire valuation on its ability to invent novel, patent-protected therapies for complex, life-threatening illnesses.
2024
The cell and gene therapy manufacturing scale-up
Novartis poured billions into building world-class manufacturing facilities for cell and gene therapies—drugs that must be tailored to the individual patient’s biology. This was a massive technical hurdle, as the manufacturing process was notoriously difficult to scale. By perfecting these logistical and biological manufacturing workflows, Novartis aimed to become the "go-to" partner for the most complex therapies in the modern medical world.
2026
The high-end innovative medicine specialist
By mid-2026, Novartis operates as a lean, focused, and high-performance pharmaceutical engine. With its generics business gone and its R&D streamlined, the Swiss giant is now an expert in high-value, patent-heavy therapeutic segments. The company’s ability to navigate the complex regulatory and manufacturing requirements of modern cell and gene medicine keeps it at the absolute pinnacle of the industry.
Frequently Asked Questions
Who founded Novartis?
Novartis was founded by Merger of Ciba-Geigy and Sandoz.
When was Novartis founded?
Novartis was founded in 1996.
Where was Novartis founded?
Novartis was headquartered in Basel, Switzerland.
Why was Novartis created?
Novartis was born from the colossal, record-breaking merger of two historic Swiss chemical and pharmaceutical giants: Ciba-Geigy and Sandoz. The new entity was immediately one of the largest pharmaceutical companies in the world. However, the company was initially bloated, with vast interests in everything from agricultural chemicals to food products, forcing the new management team to undertake a massive, multi-year process of selling off divisions to focus exclusively on pharmaceuticals.
What does Novartis do?
The result of the largest corporate merger in history that focused on shedding its chemical divisions to become a pure-play medicine research giant. Explore the story of Novartis, born from the largest merger in history and transformed into a high-performance pure-play pharmaceutical specialist.
How did Novartis grow?
By mid-2026, Novartis operates as a lean, focused, and high-performance pharmaceutical engine. With its generics business gone and its R&D streamlined, the Swiss giant is now an expert in high-value, patent-heavy therapeutic segments. The company’s ability to navigate the complex regulatory and manufacturing requirements of modern cell and gene medicine keeps it at the absolute pinnacle of the industry.
Also in The Garage